Abstract 127P
Background
Although tumor budding (TB) has been recognized as a representative adverse prognosticator in gastrointestinal malignancies, it is not well elucidated in distal-extrahepatic bile duct carcinoma (DBDC).
Methods
Herein, we investigated the prognostic significance of peritumoral (PTB) and intratumoral (ITB) budding according to the modified DBDC staging of the 8th edition of the American Joint Committee on Cancer. PTB and ITB were independently evaluated in a cohort of DBDC patients (n=410) based on the 2016 International Tumor Budding Consensus Conference (ITBCC).
Results
High levels of PTB (PTBHigh, ≥ grade 2) and ITB (ITBHigh, ≥ grade 3) were identified in 316 (77%) and 238 (58%) cases, respectively. In univariate analysis, PTBHigh and ITBHigh (both P=0.001); larger size and sclerosing tumor growth pattern (both P<0.001); higher histologic grade (P=0.006); extrapancreatic location (P=0.015); adenocarcinomas unrelated to intraductal papillary neoplasm of the bile duct (IPNB) (P=0.008); pancreatic, duodenal, and lymphovascular invasion (all P<0.001); perineural invasion (P=0.003); cancer involvement of the bile duct resection margin, nodal metastasis, and higher T and N categories and disease stages (all P<0.001) were associated with shorter patient overall survival (OS) times. In multivariate analysis, PTBHigh and ITBHigh remained poor independent prognostic indicators of OS in DBDC patients. Specifically, ITBHigh could predict poor prognosis (P=0.025) in patients with stage I (T1N0) DBDC.
Conclusions
Both PTBHigh and ITBHigh were strong prognostic indicators in patients with DBDC. Thus, ITB could be used to predict worse prognoses in patients with DBDC, in which PTB is difficult to assess, especially for patients with stage I (T1N0) DBDC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
97P - Neoadjuvant durvalumab plus gemcitabine and cisplatin (D+GemCis) versus gemcis alone for localized biliary tract cancer (BTC): Results of a randomized, multicenter, open-label, phase II trial (DEBATE)
Presenter: Changhoon Yoo
Session: Poster session 17
101P - Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 study
Presenter: Harpreet Wasan
Session: Poster session 17
102P - Potentially prognostic factors of overall survival in advanced biliary tract cancer in the randomised phase III TOPAZ-1 study
Presenter: Aiwu Ruth He
Session: Poster session 17
103P - Individual patient data (IPD) meta-analysis of randomised trials to compare efficacy of second-line fluoropyrimidine-based chemotherapy in advanced biliary tract cancer (BTC)
Presenter: Jaewon Hyung
Session: Poster session 17
104P - Final analysis of the prospective, randomized phase II STAMP trial: Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in node-positive extrahepatic cholangiocarcinoma (CCA)
Presenter: Hyehyun Jeong
Session: Poster session 17
105P - A phase II study of SHR-1316 plus IBI310 in patients with advanced intrahepatic cholangiocarcinoma after failure of first-line therapy
Presenter: Jia Fan
Session: Poster session 17